Lowe G D, Morrice J J, Fulton A, Forbes C D, Prentice C R, Barbenel J C
Thromb Haemost. 1978 Aug 31;40(1):134-43.
We have conducted a dose-ranging and feasibility study of daily subcutaneous injections of ancrod (Arvin) as a potential antithrombotic method in 28 patients following operation for fractured neck of femur. Sustained, predictable fibrinogen depletion during the first post-operative week was induced by four different regimes. A total dose of 10 units/kg weight, given in divided doses starting on the day of operation, is suggested as a possible antithrombotic regime. Ancrod treatment produced a rise in fibrinogen/fibrin degradation products, prolongation of the thrombin clotting time, and a fall in plasminogen, plasma fibrinogen and corrected blood viscosity were observed in 14 control patients. Plasma fibrinogen was correlated with plasma viscosity and corrected blood viscosity. No adverse effects of treatment occurred. Subcutaneous ancrod appears to be a simple, safe, and feasible potential antithrombotic method, and merits trials of efficacy in the prevention of post-operative thromboembolism.
我们对28例股骨颈骨折术后患者进行了一项剂量范围和可行性研究，以探讨每日皮下注射抗栓酶（安克洛酶）作为一种潜在抗栓方法的效果。通过四种不同方案诱导术后第一周内持续、可预测的纤维蛋白原消耗。建议从手术当天开始分剂量给予总剂量为10单位/千克体重，作为一种可能的抗栓方案。在14例对照患者中观察到，抗栓酶治疗导致纤维蛋白原/纤维蛋白降解产物升高、凝血酶凝血时间延长，以及纤溶酶原、血浆纤维蛋白原下降和校正血液粘度降低。血浆纤维蛋白原与血浆粘度和校正血液粘度相关。未出现治疗的不良反应。皮下注射抗栓酶似乎是一种简单、安全且可行的潜在抗栓方法，值得进行预防术后血栓栓塞疗效的试验。
